Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Bristol-Myers Squibb | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Nivolumab obtained European Marketing authorization in June 2015. Before this date, a Temporary Authorization for Use (ATU) Program in France for nivolumab was set up between September 2014 and August 2015. This program enrolled approximately 600 melanoma patients (unresectable or metastatic).
It appears relevant to conduct a study on patients treated during the ATU to assess thoroughly patient characteristics, efficacy, safety, and patterns of use of nivolumab in real-life conditions.
In order to reach goals of this study, collaboration had been established between BMS and the RIC-Mel network (network for Research and Clinical Investigational Research on Melanoma) (NCT03315468).
The RIC-Mel network has set up a national database in order to reference the active file of melanoma patients in France. The RIC-Mel database, supported by Nantes University Hospital, had been approved by French authorities (CCTIRS and CNIL). The RIC-Mel network is coordinated by Pr B. DRENO (Nantes University Hospital) and Pr C. LEBBE (Saint-Louis Hospital, AP-HP, Paris). Nowadays, 49 centres located all over the country are participating, with more than 19,000 melanoma patients included in the database. The RIC-Mel database is referred as one of the privileged access to any research program on melanoma by the Cancerology Group (GCC) of the French Society of Dermatology .
Based on this, BMS and the RIC-Mel network had established a partnership to set up a study in order to estimate the overall survival of melanoma patients treated by Nivolumab during the French ATU program.
Data are collected in the RIC-Mel database by participating centres. Information of centres, follow-up of activity, data reviewing and extractions are realized by the RIC-Mel network. Data analysis is performed by BMS following a developed statistical protocol.
Patients included in the study were patients with unresectable or advanced metastatic melanoma, which received at least one of Nivolumab, dispensed during the French ATU program.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Routine care | Other | This study is an observational one - there is no change to the routine care. Patients received the Nivolumab independently of the study. Only data will be collected during this project. |
| Measure | Description | Time Frame |
|---|---|---|
| Overall Survival of patients included in the study thanks to subgroups of interest | Overall survival is defined as the time from index date (initiation of Nivolumab) until date of death due to any cause. Overall survival will be censored on the last date a subject was known to be alive. Estimates of survival rates will be realized for 1-year and 2-year survival. Median time will also be calculated. Subgroups of interest are described in the description of the first Secondary Outcome Measure. Safety Issue: No | 2 years |
| Measure | Description | Time Frame |
|---|---|---|
| Distribution of melanoma patients included in the study in all subgroups of interest thanks to their clinical features at the time of treatment initiation | Subgroups of interest, based on information collected in medical records, were :
|
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
patients
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Brigitte DRENO, PU-PH | Nantes University Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| AP-HP Hôpital Ambroise Paré | Paris | Boulogne Billancourt | 992100 | France | ||
| CHU de Grenoble |
Not provided
| ID | Term |
|---|---|
| D008545 | Melanoma |
| ID | Term |
|---|---|
| D018358 | Neuroendocrine Tumors |
| D017599 | Neuroectodermal Tumors |
| D009373 | Neoplasms, Germ Cell and Embryonal |
| D009370 | Neoplasms by Histologic Type |
Not provided
Not provided
Not provided
Not provided
Not provided
| Day 1 |
| Proportion of melanoma patients included in the study categorized by genders overall and by subgroups of interest | Distribution of females and males. This analyse will be performed for all the study population and by subgroups of interest (as defined in the primary Outcome Measure).Safety Issue: No | Day 1 |
| Distribution of age of melanoma patients included in the study overall and by subgroups of interest | Age of patients is the age at the start of Nivolumab treatment Safety Issue: No | Day 1 |
| Description of Nivolumab treatment of melanoma patients included in the study | Average and median of Nivolumab treatment duration and infusion number will be assessed. Median time to discontinuation, whatever the reason and median time to discontinuation of dose related to adverse events. Distribution of reasons for discontinuation. Safety Issue: No | 2 years |
| Incidence of select grade 3, 4 and 5 adverse events (AE) in melanoma patients included in the study and related to Nivolumab treatment | An AE is defined as any undesirable experience or manifestation associated with the use of a medical product in a patient. AEs are categorized by grades, which refer to severity : Grade 3 - Severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated, disabling, limiting self-care activities of daily living, Grade 4 - Life-threatening consequences, urgent intervention indicated, Grade 5 - Death related to AE. Proportion of patients with at least one or more select AE, distribution, average and median time of AE occurrence, duration and evolution of AEs as well as description of action on Nivolumab treatment will also be assessed. Safety Issue: Yes | 2 years |
| Progression-free survival of melanoma patients included in the study | Progression-free survival is defined as the time since Nivolumab initiation to either the first disease progression date or at last known tumour assessment date, or death due to any cause, whichever occurs first. Safety Issue: No | 2 years |
| Objective response rate of melanoma patients included in the study | Objective response rate as the number of subjects with a best objective response of either a partial response of a complete response. Objective response rate is the proportion of patients with an objective response. Safety Issue: No | 2 years |
| Grenoble |
| La Tronche |
| 38700 |
| France |
| Chu Amiens | Amiens | 80408 | France |
| Hopital St andré-CHU DE Bordeaux | Bordeaux | 33000 | France |
| Chu Clermont-Ferrand | Clermont-Ferrand | 63000 | France |
| Chu Dijon | Dijon | 21000 | France |
| CH du Mans | Le Mans | 72000 | France |
| Chru Lille | Lille | 59000 | France |
| Centre Léon Bérard de Lyon | Lyon | 69008 | France |
| Hospices Civils de Lyon: Lyon Sud | Lyon | 69229 | France |
| Hôpitaux de Marseille | Marseille | 13000 | France |
| CHU NICE | Nice | 06000 | France |
| CH de PAU | Pau | 64000 | France |
| CHU de Rouen | Rouen | 76038 | France |
| Chu Toulouse | Toulouse | 31000 | France |
| Ch Valence | Valence | 26000 | France |
| Institut Gustave Roussy | Villejuif | 94800 | France |
| D009369 | Neoplasms |
| D009380 | Neoplasms, Nerve Tissue |
| D018326 | Nevi and Melanomas |
| D012878 | Skin Neoplasms |
| D009371 | Neoplasms by Site |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |